Certified by Founder
Lodge
Sionna Therapeutics
start up
United States
- Boston, MA
- 07/03/2024
- Series C
- $182,000,000
We are a life sciences company that is building on over a decade of extensive research on the genetic mutations associated with cystic fibrosis. We are developing first-in-class small molecules that are focused on a unique target with the potential to fully normalize CFTR function for the first time for the vast majority of people living with CF.
- Industry Biotechnology
- Website https://www.sionnatx.com/
- LinkedIn https://www.linkedin.com/company/sionna-therapeutics/
Fanvue | $22,000,000 | (Jan 20, 2026)
Dominion Dynamics | $15,200,000 | (Jan 20, 2026)
Tulip Interfaces | $120,000,000 | (Jan 20, 2026)
Fleetzero | $43,000,000 | (Jan 20, 2026)
EXCIVA GmbH | $59,817,135 | (Jan 20, 2026)
Transition Metal Solutions | $6,000,000 | (Jan 20, 2026)
one • fıve | $16,320,500 | (Jan 20, 2026)
Anzen Industries | $2,283,975 | (Jan 20, 2026)
Gutology | $2,418,300 | (Jan 20, 2026)
GovDash | $30,000,000 | (Jan 16, 2026)
RouteSense | $2,000,000 | (Jan 16, 2026)
Vista AI | $29,500,000 | (Jan 16, 2026)